Schistosoma mansoni 29 kDa tegumental protein (Sm29) (Sm29)

Schistosoma mansoni 29 kDa tegumental protein (Sm29) is a membrane-bound antigen located on the surface of the adult worm and schistosomula stages of the parasite (UniProt Q869A6). It plays a crucial role in the interaction between the parasite and the host's immune system, making it a prominent candidate for vaccine development against schistosomiasis. Research indicates that Sm29 is highly immunogenic and can induce a protective immune response, primarily through Th1-mediated pathways involving interferon-gamma and specific IgG subclasses (Pinheiro et al., 2011). In animal models, vaccination with recombinant Sm29 has demonstrated a significant reduction in worm burden, intestinal egg counts, and liver granuloma formation (Cardoso et al., 2008). While no small molecule drugs currently target Sm29, it is being actively investigated in clinical and preclinical vaccine formulations, often in combination with other schistosome antigens to enhance efficacy. Its localization on the tegument makes it accessible to host antibodies and immune cells, facilitating parasite clearance. The protein is considered a high-priority target due to its consistent expression across different life stages of the parasite.

Other names

Sm2929 kDa tegumental antigenSchistosoma mansoni 29 kDa surface proteinSM_29

Induction of a Th1-type immune response and production of specific IgG antibodies (IgG1 and IgG3) that target the parasite tegument, leading to immune-mediated destruction of the worm (Cardoso et al., 2008; Pinheiro et al., 2011).